Sharman, J., Hawkins, M., Kolibaba, K., Boxer, M., Klein, L., Wu, M., . . . Yasenchak, C. (2015). An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood.

Sharman, Jeff, Michael Hawkins, Kathryn Kolibaba, Michael Boxer, Leonard Klein, Meihua Wu, Jing Hu, Steve Abella, and Chris Yasenchak. "An Open-label Phase 2 Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Chronic Lymphocytic Leukemia." Blood 2015.

Sharman, Jeff, et al. "An Open-label Phase 2 Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Chronic Lymphocytic Leukemia." Blood 2015.